APOA1 Is a Novel Marker for Preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Cardiovascular Biology
• Molecular Medicine

Background:

• Preeclampsia (PE) is a significant pregnancy complication with unclear underlying mechanisms.
• Identifying novel biomarkers and therapeutic targets for PE is crucial for improving maternal and fetal outcomes.

Purpose of the Study:

• To investigate the role of apolipoprotein A1 (APOA1) in the pathophysiology of preeclampsia.
• To explore the relationship between APOA1 levels and clinical parameters in PE patients.

Main Methods:

• Western blotting, immunohistochemistry, and qRT-PCR to assess APOA1 expression in plasma and placental tissues.
• ELISA assay to quantify APOA1 concentration in normal pregnant (NP) and PE patients.
• In vitro studies using HTR8/SVneo cells to evaluate the effects of APOA1 on trophoblast proliferation and invasion.
• Luciferase assay to investigate the interaction between APOA1 and peroxisome proliferator-activated receptor gamma (PPARγ).

Main Results:

• APOA1 expression was elevated in both plasma and placental tissues of PE patients.
• APOA1 concentration increased in late gestation PE and correlated positively with systolic blood pressure.
• APOA1 modulated trophoblast proliferation and invasion in vitro, with effects mediated by PPARγ.
• APOA1 promoter activity was enhanced by PPARγ, and its inhibitory effects on trophoblast function were reversible by a PPARγ inhibitor.

Conclusions:

• APOLIPOPROTEIN A1 plays a critical role in the pathophysiology of preeclampsia.
• APOA1 may serve as a potential biomarker for PE and a novel therapeutic target for its prevention and treatment.